ProGREsS

  • Research type

    Research Study

  • Full title

    Personalised Genetic Risk Estimates for Cancer Screening & Prevention

  • IRAS ID

    213897

  • Contact name

    J Krell

  • Contact email

    j.krell@imperial.ac.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    This is a 2-part study and combines a questionnaire study within the general population with a personalised cancer risk assessment study in a smaller group of women.

    Part 1 involves the completion of an online questionnaire by the local population and the aim is to evaluate the awareness and understanding of genetic testing within this population.

    Part 2 will be done in GP practices within the local area. Women will be asked to provide blood and saliva samples and complete a questionnaire. These data will be analysed to produce an individualised breast and ovarian cancer risk score. Patients will be advised of their risk score and prevention strategies and the study will look in detail at changes in the epigenome with use of the oral contraceptive pill. The aim of part 2 is to help determine whether risk assessment calculations can help patients to make informed decisions about disease prevention behaviours. The study will also analyse whether the use of family history and epidemiological factors can be used to streamline cancer genetic testing in the primary care setting

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    18/EM/0070

  • Date of REC Opinion

    4 Jun 2018

  • REC opinion

    Further Information Favourable Opinion